March 24 (Reuters) – The European Union’s medicines regulator said on Tuesday it expects Baxter International’s cancer drugs containing ifosfamide will remain in shortage in the bloc well into the first quarter of next year.
Ifosfamide is used by itself or in combination with other therapies to treat multiple cancers including testicular, small cell and cervical cancers.
The European Medicines Agency said the shortage was due to a technical disruption at Baxter’s contract manufacturing site, but did not disclose details.
(Reporting by Prerna Bedi in Bengaluru; additional reporting by Rishab Shaju; Editing by Leroy Leo)
